nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—Neck pain—Lisinopril—dilated cardiomyopathy	0.00284	0.00315	CcSEcCtD
Escitalopram—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00284	0.00315	CcSEcCtD
Escitalopram—Purpura—Furosemide—dilated cardiomyopathy	0.00282	0.00313	CcSEcCtD
Escitalopram—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00281	0.00312	CcSEcCtD
Escitalopram—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.00281	0.00312	CcSEcCtD
Escitalopram—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00279	0.0031	CcSEcCtD
Escitalopram—Lethargy—Furosemide—dilated cardiomyopathy	0.00277	0.00308	CcSEcCtD
Escitalopram—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00274	0.00304	CcSEcCtD
Escitalopram—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00273	0.00303	CcSEcCtD
Escitalopram—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.00273	0.00303	CcSEcCtD
Escitalopram—Salivary hypersecretion—Lisinopril—dilated cardiomyopathy	0.00273	0.00303	CcSEcCtD
Escitalopram—Wheezing—Lisinopril—dilated cardiomyopathy	0.00273	0.00303	CcSEcCtD
Escitalopram—Malaise—Spironolactone—dilated cardiomyopathy	0.00271	0.00301	CcSEcCtD
Escitalopram—Cystitis—Lisinopril—dilated cardiomyopathy	0.00271	0.00301	CcSEcCtD
Escitalopram—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00269	0.00299	CcSEcCtD
Escitalopram—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00266	0.00296	CcSEcCtD
Escitalopram—Photophobia—Lisinopril—dilated cardiomyopathy	0.00264	0.00293	CcSEcCtD
Escitalopram—Neuropathy—Lisinopril—dilated cardiomyopathy	0.00264	0.00293	CcSEcCtD
Escitalopram—Irritability—Furosemide—dilated cardiomyopathy	0.00259	0.00288	CcSEcCtD
Escitalopram—Urinary retention—Furosemide—dilated cardiomyopathy	0.00258	0.00287	CcSEcCtD
Escitalopram—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00254	0.00282	CcSEcCtD
Escitalopram—Discomfort—Spironolactone—dilated cardiomyopathy	0.00253	0.00281	CcSEcCtD
Escitalopram—Dehydration—Furosemide—dilated cardiomyopathy	0.00253	0.0028	CcSEcCtD
Escitalopram—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.00251	0.00279	CcSEcCtD
Escitalopram—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00248	0.00275	CcSEcCtD
Escitalopram—Confusional state—Spironolactone—dilated cardiomyopathy	0.00247	0.00275	CcSEcCtD
Escitalopram—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00247	0.00274	CcSEcCtD
Escitalopram—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00246	0.00273	CcSEcCtD
Escitalopram—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00245	0.00272	CcSEcCtD
Escitalopram—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00245	0.00272	CcSEcCtD
Escitalopram—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00245	0.00272	CcSEcCtD
Escitalopram—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.0024	0.00267	CcSEcCtD
Escitalopram—Muscular weakness—Furosemide—dilated cardiomyopathy	0.0024	0.00266	CcSEcCtD
Escitalopram—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00236	0.00262	CcSEcCtD
Escitalopram—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00235	0.00261	CcSEcCtD
Escitalopram—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00234	0.0026	CcSEcCtD
Escitalopram—Eosinophilia—Furosemide—dilated cardiomyopathy	0.00232	0.00258	CcSEcCtD
Escitalopram—Pancreatitis—Furosemide—dilated cardiomyopathy	0.0023	0.00256	CcSEcCtD
Escitalopram—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.0023	0.00255	CcSEcCtD
Escitalopram—Eczema—Lisinopril—dilated cardiomyopathy	0.00227	0.00252	CcSEcCtD
Escitalopram—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00227	0.00252	CcSEcCtD
Escitalopram—Haemolytic anaemia—Lisinopril—dilated cardiomyopathy	0.00226	0.00251	CcSEcCtD
Escitalopram—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.00224	0.00248	CcSEcCtD
Escitalopram—Injury—Lisinopril—dilated cardiomyopathy	0.00222	0.00246	CcSEcCtD
Escitalopram—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00221	0.00245	CcSEcCtD
Escitalopram—Libido decreased—Lisinopril—dilated cardiomyopathy	0.0022	0.00244	CcSEcCtD
Escitalopram—Somnolence—Spironolactone—dilated cardiomyopathy	0.00218	0.00242	CcSEcCtD
Escitalopram—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00217	0.00241	CcSEcCtD
Escitalopram—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00215	0.00239	CcSEcCtD
Escitalopram—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00214	0.00238	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00212	0.00235	CcSEcCtD
Escitalopram—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00212	0.00235	CcSEcCtD
Escitalopram—Arthritis—Lisinopril—dilated cardiomyopathy	0.0021	0.00233	CcSEcCtD
Escitalopram—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00209	0.00232	CcSEcCtD
Escitalopram—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00208	0.00231	CcSEcCtD
Escitalopram—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00207	0.0023	CcSEcCtD
Escitalopram—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00205	0.00227	CcSEcCtD
Escitalopram—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00204	0.00226	CcSEcCtD
Escitalopram—Diplopia—Lisinopril—dilated cardiomyopathy	0.00204	0.00226	CcSEcCtD
Escitalopram—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00204	0.00226	CcSEcCtD
Escitalopram—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00202	0.00224	CcSEcCtD
Escitalopram—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00202	0.00224	CcSEcCtD
Escitalopram—Sweating—Furosemide—dilated cardiomyopathy	0.00201	0.00223	CcSEcCtD
Escitalopram—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00198	0.0022	CcSEcCtD
Escitalopram—Face oedema—Lisinopril—dilated cardiomyopathy	0.00197	0.00218	CcSEcCtD
Escitalopram—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00195	0.00217	CcSEcCtD
Escitalopram—Urticaria—Spironolactone—dilated cardiomyopathy	0.00195	0.00216	CcSEcCtD
Escitalopram—Irritability—Lisinopril—dilated cardiomyopathy	0.00194	0.00216	CcSEcCtD
Escitalopram—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00194	0.00215	CcSEcCtD
Escitalopram—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.00194	0.00215	CcSEcCtD
Escitalopram—Ataxia—Lisinopril—dilated cardiomyopathy	0.00192	0.00213	CcSEcCtD
Escitalopram—Dehydration—Lisinopril—dilated cardiomyopathy	0.00189	0.0021	CcSEcCtD
Escitalopram—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00186	0.00207	CcSEcCtD
Escitalopram—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00186	0.00206	CcSEcCtD
Escitalopram—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00184	0.00204	CcSEcCtD
Escitalopram—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00184	0.00204	CcSEcCtD
Escitalopram—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00183	0.00204	CcSEcCtD
Escitalopram—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.00183	0.00204	CcSEcCtD
Escitalopram—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00182	0.00202	CcSEcCtD
Escitalopram—Visual impairment—Furosemide—dilated cardiomyopathy	0.00181	0.00201	CcSEcCtD
Escitalopram—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00181	0.00201	CcSEcCtD
Escitalopram—Gastritis—Lisinopril—dilated cardiomyopathy	0.0018	0.002	CcSEcCtD
Escitalopram—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00178	0.00197	CcSEcCtD
Escitalopram—Influenza—Lisinopril—dilated cardiomyopathy	0.00176	0.00196	CcSEcCtD
Escitalopram—Asthma—Lisinopril—dilated cardiomyopathy	0.00176	0.00196	CcSEcCtD
Escitalopram—Eye disorder—Furosemide—dilated cardiomyopathy	0.00176	0.00195	CcSEcCtD
Escitalopram—Tinnitus—Furosemide—dilated cardiomyopathy	0.00175	0.00194	CcSEcCtD
Escitalopram—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.00174	0.00194	CcSEcCtD
Escitalopram—Pruritus—Spironolactone—dilated cardiomyopathy	0.00174	0.00193	CcSEcCtD
Escitalopram—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.00173	0.00192	CcSEcCtD
Escitalopram—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00173	0.00192	CcSEcCtD
Escitalopram—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00172	0.0019	CcSEcCtD
Escitalopram—Sweating increased—Lisinopril—dilated cardiomyopathy	0.00172	0.0019	CcSEcCtD
Escitalopram—Angiopathy—Furosemide—dilated cardiomyopathy	0.0017	0.00189	CcSEcCtD
Escitalopram—Immune system disorder—Furosemide—dilated cardiomyopathy	0.0017	0.00188	CcSEcCtD
Escitalopram—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00169	0.00188	CcSEcCtD
Escitalopram—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00168	0.00186	CcSEcCtD
Escitalopram—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00168	0.00186	CcSEcCtD
Escitalopram—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00167	0.00186	CcSEcCtD
Escitalopram—Dysuria—Lisinopril—dilated cardiomyopathy	0.00165	0.00183	CcSEcCtD
Escitalopram—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00164	0.00182	CcSEcCtD
Escitalopram—Malnutrition—Furosemide—dilated cardiomyopathy	0.00164	0.00182	CcSEcCtD
Escitalopram—Erythema—Furosemide—dilated cardiomyopathy	0.00164	0.00182	CcSEcCtD
Escitalopram—Dizziness—Spironolactone—dilated cardiomyopathy	0.00162	0.0018	CcSEcCtD
Escitalopram—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00162	0.0018	CcSEcCtD
Escitalopram—Flatulence—Furosemide—dilated cardiomyopathy	0.00161	0.00179	CcSEcCtD
Escitalopram—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00161	0.00178	CcSEcCtD
Escitalopram—Weight increased—Lisinopril—dilated cardiomyopathy	0.0016	0.00178	CcSEcCtD
Escitalopram—Dysgeusia—Furosemide—dilated cardiomyopathy	0.0016	0.00178	CcSEcCtD
Escitalopram—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00159	0.00177	CcSEcCtD
Escitalopram—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00159	0.00176	CcSEcCtD
Escitalopram—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00158	0.00175	CcSEcCtD
Escitalopram—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00157	0.00175	CcSEcCtD
Escitalopram—Depression—Lisinopril—dilated cardiomyopathy	0.00157	0.00174	CcSEcCtD
Escitalopram—Vomiting—Spironolactone—dilated cardiomyopathy	0.00156	0.00173	CcSEcCtD
Escitalopram—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00156	0.00173	CcSEcCtD
Escitalopram—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00155	0.00172	CcSEcCtD
Escitalopram—Rash—Spironolactone—dilated cardiomyopathy	0.00155	0.00172	CcSEcCtD
Escitalopram—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00155	0.00172	CcSEcCtD
Escitalopram—Vision blurred—Furosemide—dilated cardiomyopathy	0.00154	0.00171	CcSEcCtD
Escitalopram—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00154	0.00171	CcSEcCtD
Escitalopram—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00154	0.00171	CcSEcCtD
Escitalopram—Headache—Spironolactone—dilated cardiomyopathy	0.00154	0.00171	CcSEcCtD
Escitalopram—Jaundice—Lisinopril—dilated cardiomyopathy	0.00153	0.0017	CcSEcCtD
Escitalopram—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00153	0.00169	CcSEcCtD
Escitalopram—Anaemia—Furosemide—dilated cardiomyopathy	0.00151	0.00168	CcSEcCtD
Escitalopram—Sweating—Lisinopril—dilated cardiomyopathy	0.00151	0.00167	CcSEcCtD
Escitalopram—Agitation—Furosemide—dilated cardiomyopathy	0.0015	0.00167	CcSEcCtD
Escitalopram—Haematuria—Lisinopril—dilated cardiomyopathy	0.0015	0.00166	CcSEcCtD
Escitalopram—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00148	0.00165	CcSEcCtD
Escitalopram—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00148	0.00164	CcSEcCtD
Escitalopram—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00147	0.00164	CcSEcCtD
Escitalopram—Vertigo—Furosemide—dilated cardiomyopathy	0.00147	0.00163	CcSEcCtD
Escitalopram—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.00147	0.00163	CcSEcCtD
Escitalopram—Leukopenia—Furosemide—dilated cardiomyopathy	0.00146	0.00163	CcSEcCtD
Escitalopram—Nausea—Spironolactone—dilated cardiomyopathy	0.00146	0.00162	CcSEcCtD
Escitalopram—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00143	0.00159	CcSEcCtD
Escitalopram—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00141	0.00157	CcSEcCtD
Escitalopram—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00141	0.00157	CcSEcCtD
Escitalopram—Hallucination—Lisinopril—dilated cardiomyopathy	0.0014	0.00156	CcSEcCtD
Escitalopram—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.0014	0.00155	CcSEcCtD
Escitalopram—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00139	0.00155	CcSEcCtD
Escitalopram—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00139	0.00154	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00138	0.00154	CcSEcCtD
Escitalopram—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00138	0.00153	CcSEcCtD
Escitalopram—Dry mouth—Furosemide—dilated cardiomyopathy	0.00136	0.00151	CcSEcCtD
Escitalopram—Confusional state—Furosemide—dilated cardiomyopathy	0.00135	0.00149	CcSEcCtD
Escitalopram—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00133	0.00148	CcSEcCtD
Escitalopram—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00133	0.00148	CcSEcCtD
Escitalopram—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00131	0.00146	CcSEcCtD
Escitalopram—Shock—Furosemide—dilated cardiomyopathy	0.00131	0.00146	CcSEcCtD
Escitalopram—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00131	0.00145	CcSEcCtD
Escitalopram—Flushing—Lisinopril—dilated cardiomyopathy	0.00131	0.00145	CcSEcCtD
Escitalopram—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00131	0.00145	CcSEcCtD
Escitalopram—Skin disorder—Furosemide—dilated cardiomyopathy	0.0013	0.00144	CcSEcCtD
Escitalopram—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00129	0.00143	CcSEcCtD
Escitalopram—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00128	0.00142	CcSEcCtD
Escitalopram—Anorexia—Furosemide—dilated cardiomyopathy	0.00127	0.00141	CcSEcCtD
Escitalopram—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00127	0.00141	CcSEcCtD
Escitalopram—Chills—Lisinopril—dilated cardiomyopathy	0.00126	0.0014	CcSEcCtD
Escitalopram—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00126	0.0014	CcSEcCtD
Escitalopram—Hypotension—Furosemide—dilated cardiomyopathy	0.00125	0.00138	CcSEcCtD
Escitalopram—Alopecia—Lisinopril—dilated cardiomyopathy	0.00125	0.00138	CcSEcCtD
Escitalopram—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00123	0.00137	CcSEcCtD
Escitalopram—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00123	0.00136	CcSEcCtD
Escitalopram—Erythema—Lisinopril—dilated cardiomyopathy	0.00123	0.00136	CcSEcCtD
Escitalopram—Flatulence—Lisinopril—dilated cardiomyopathy	0.00121	0.00134	CcSEcCtD
Escitalopram—Tension—Lisinopril—dilated cardiomyopathy	0.0012	0.00134	CcSEcCtD
Escitalopram—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.0012	0.00133	CcSEcCtD
Escitalopram—Paraesthesia—Furosemide—dilated cardiomyopathy	0.0012	0.00133	CcSEcCtD
Escitalopram—Nervousness—Lisinopril—dilated cardiomyopathy	0.00119	0.00132	CcSEcCtD
Escitalopram—Back pain—Lisinopril—dilated cardiomyopathy	0.00119	0.00132	CcSEcCtD
Escitalopram—Somnolence—Furosemide—dilated cardiomyopathy	0.00119	0.00132	CcSEcCtD
Escitalopram—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00118	0.00131	CcSEcCtD
Escitalopram—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00116	0.00129	CcSEcCtD
Escitalopram—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00116	0.00128	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00115	0.00128	CcSEcCtD
Escitalopram—Fatigue—Furosemide—dilated cardiomyopathy	0.00115	0.00128	CcSEcCtD
Escitalopram—Tremor—Lisinopril—dilated cardiomyopathy	0.00115	0.00128	CcSEcCtD
Escitalopram—Pain—Furosemide—dilated cardiomyopathy	0.00114	0.00127	CcSEcCtD
Escitalopram—Constipation—Furosemide—dilated cardiomyopathy	0.00114	0.00127	CcSEcCtD
Escitalopram—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00114	0.00126	CcSEcCtD
Escitalopram—Anaemia—Lisinopril—dilated cardiomyopathy	0.00113	0.00126	CcSEcCtD
Escitalopram—Angioedema—Lisinopril—dilated cardiomyopathy	0.00112	0.00124	CcSEcCtD
Escitalopram—Malaise—Lisinopril—dilated cardiomyopathy	0.00111	0.00123	CcSEcCtD
Escitalopram—Vertigo—Lisinopril—dilated cardiomyopathy	0.0011	0.00122	CcSEcCtD
Escitalopram—Syncope—Lisinopril—dilated cardiomyopathy	0.0011	0.00122	CcSEcCtD
Escitalopram—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.0011	0.00122	CcSEcCtD
Escitalopram—Leukopenia—Lisinopril—dilated cardiomyopathy	0.0011	0.00122	CcSEcCtD
Escitalopram—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00109	0.00121	CcSEcCtD
Escitalopram—Palpitations—Lisinopril—dilated cardiomyopathy	0.00108	0.0012	CcSEcCtD
Escitalopram—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00108	0.0012	CcSEcCtD
Escitalopram—Cough—Lisinopril—dilated cardiomyopathy	0.00107	0.00119	CcSEcCtD
Escitalopram—Urticaria—Furosemide—dilated cardiomyopathy	0.00106	0.00118	CcSEcCtD
Escitalopram—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00106	0.00117	CcSEcCtD
Escitalopram—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00106	0.00117	CcSEcCtD
Escitalopram—Myalgia—Lisinopril—dilated cardiomyopathy	0.00104	0.00116	CcSEcCtD
Escitalopram—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00104	0.00116	CcSEcCtD
Escitalopram—Chest pain—Lisinopril—dilated cardiomyopathy	0.00104	0.00116	CcSEcCtD
Escitalopram—Anxiety—Lisinopril—dilated cardiomyopathy	0.00104	0.00116	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00104	0.00115	CcSEcCtD
Escitalopram—Discomfort—Lisinopril—dilated cardiomyopathy	0.00103	0.00115	CcSEcCtD
Escitalopram—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00102	0.00113	CcSEcCtD
Escitalopram—Confusional state—Lisinopril—dilated cardiomyopathy	0.00101	0.00112	CcSEcCtD
Escitalopram—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.001	0.00111	CcSEcCtD
Escitalopram—Oedema—Lisinopril—dilated cardiomyopathy	0.001	0.00111	CcSEcCtD
Escitalopram—Infection—Lisinopril—dilated cardiomyopathy	0.000995	0.0011	CcSEcCtD
Escitalopram—Shock—Lisinopril—dilated cardiomyopathy	0.000985	0.00109	CcSEcCtD
Escitalopram—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000983	0.00109	CcSEcCtD
Escitalopram—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000981	0.00109	CcSEcCtD
Escitalopram—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000977	0.00109	CcSEcCtD
Escitalopram—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000973	0.00108	CcSEcCtD
Escitalopram—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000968	0.00107	CcSEcCtD
Escitalopram—Asthenia—Furosemide—dilated cardiomyopathy	0.000958	0.00106	CcSEcCtD
Escitalopram—Anorexia—Lisinopril—dilated cardiomyopathy	0.000955	0.00106	CcSEcCtD
Escitalopram—Pruritus—Furosemide—dilated cardiomyopathy	0.000944	0.00105	CcSEcCtD
Escitalopram—Hypotension—Lisinopril—dilated cardiomyopathy	0.000936	0.00104	CcSEcCtD
Escitalopram—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000913	0.00101	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000912	0.00101	CcSEcCtD
Escitalopram—Insomnia—Lisinopril—dilated cardiomyopathy	0.000906	0.00101	CcSEcCtD
Escitalopram—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000899	0.000998	CcSEcCtD
Escitalopram—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000893	0.000991	CcSEcCtD
Escitalopram—Somnolence—Lisinopril—dilated cardiomyopathy	0.00089	0.000989	CcSEcCtD
Escitalopram—Dizziness—Furosemide—dilated cardiomyopathy	0.000883	0.00098	CcSEcCtD
Escitalopram—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000882	0.000979	CcSEcCtD
Escitalopram—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000871	0.000967	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000865	0.00096	CcSEcCtD
Escitalopram—Fatigue—Lisinopril—dilated cardiomyopathy	0.000863	0.000959	CcSEcCtD
Escitalopram—Constipation—Lisinopril—dilated cardiomyopathy	0.000856	0.000951	CcSEcCtD
Escitalopram—Pain—Lisinopril—dilated cardiomyopathy	0.000856	0.000951	CcSEcCtD
Escitalopram—Vomiting—Furosemide—dilated cardiomyopathy	0.000849	0.000942	CcSEcCtD
Escitalopram—Rash—Furosemide—dilated cardiomyopathy	0.000842	0.000934	CcSEcCtD
Escitalopram—Dermatitis—Furosemide—dilated cardiomyopathy	0.000841	0.000934	CcSEcCtD
Escitalopram—Headache—Furosemide—dilated cardiomyopathy	0.000836	0.000928	CcSEcCtD
Escitalopram—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000825	0.000916	CcSEcCtD
Escitalopram—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000819	0.000909	CcSEcCtD
Escitalopram—Urticaria—Lisinopril—dilated cardiomyopathy	0.000796	0.000883	CcSEcCtD
Escitalopram—Nausea—Furosemide—dilated cardiomyopathy	0.000793	0.00088	CcSEcCtD
Escitalopram—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000792	0.000879	CcSEcCtD
Escitalopram—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000792	0.000879	CcSEcCtD
Escitalopram—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000738	0.000819	CcSEcCtD
Escitalopram—Asthenia—Lisinopril—dilated cardiomyopathy	0.000719	0.000798	CcSEcCtD
Escitalopram—Pruritus—Lisinopril—dilated cardiomyopathy	0.000709	0.000787	CcSEcCtD
Escitalopram—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000685	0.000761	CcSEcCtD
Escitalopram—Dizziness—Lisinopril—dilated cardiomyopathy	0.000662	0.000735	CcSEcCtD
Escitalopram—Vomiting—Lisinopril—dilated cardiomyopathy	0.000637	0.000707	CcSEcCtD
Escitalopram—Rash—Lisinopril—dilated cardiomyopathy	0.000631	0.000701	CcSEcCtD
Escitalopram—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000631	0.0007	CcSEcCtD
Escitalopram—Headache—Lisinopril—dilated cardiomyopathy	0.000627	0.000697	CcSEcCtD
Escitalopram—Nausea—Lisinopril—dilated cardiomyopathy	0.000595	0.00066	CcSEcCtD
Escitalopram—HTR2C—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000325	0.00327	CbGpPWpGaD
Escitalopram—HTR2C—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000315	0.00317	CbGpPWpGaD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.000311	0.00313	CbGpPWpGaD
Escitalopram—HRH1—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000303	0.00305	CbGpPWpGaD
Escitalopram—CHRM1—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000302	0.00304	CbGpPWpGaD
Escitalopram—HRH1—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.000301	0.00303	CbGpPWpGaD
Escitalopram—CHRM1—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.0003	0.00302	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000299	0.00301	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000299	0.00301	CbGpPWpGaD
Escitalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000297	0.00299	CbGpPWpGaD
Escitalopram—ADRA1A—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.000296	0.00297	CbGpPWpGaD
Escitalopram—HRH1—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000282	0.00283	CbGpPWpGaD
Escitalopram—CHRM1—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000281	0.00282	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000278	0.0028	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000278	0.00279	CbGpPWpGaD
Escitalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000276	0.00278	CbGpPWpGaD
Escitalopram—HRH1—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000273	0.00274	CbGpPWpGaD
Escitalopram—CHRM1—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000272	0.00274	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00027	0.00271	CbGpPWpGaD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.000269	0.00271	CbGpPWpGaD
Escitalopram—HTR2C—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000269	0.0027	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.000269	0.0027	CbGpPWpGaD
Escitalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000268	0.00269	CbGpPWpGaD
Escitalopram—CHRM1—Regulation of Actin Cytoskeleton—RAC1—dilated cardiomyopathy	0.000265	0.00267	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.000264	0.00266	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000261	0.00263	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000259	0.00261	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000259	0.00261	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000259	0.0026	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000259	0.0026	CbGpPWpGaD
Escitalopram—HTR2C—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000255	0.00257	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000255	0.00256	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000255	0.00256	CbGpPWpGaD
Escitalopram—HTR2C—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000245	0.00246	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000241	0.00243	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00024	0.00242	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000237	0.00238	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000234	0.00235	CbGpPWpGaD
Escitalopram—HRH1—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000233	0.00234	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000233	0.00234	CbGpPWpGaD
Escitalopram—CHRM1—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000232	0.00234	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00023	0.00232	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000229	0.00231	CbGpPWpGaD
Escitalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000229	0.0023	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000228	0.00229	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000228	0.00229	CbGpPWpGaD
Escitalopram—HRH1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000221	0.00222	CbGpPWpGaD
Escitalopram—CHRM1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.00022	0.00222	CbGpPWpGaD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000219	0.0022	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000218	0.0022	CbGpPWpGaD
Escitalopram—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000217	0.00218	CbGpPWpGaD
Escitalopram—CHRM1—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000213	0.00214	CbGpPWpGaD
Escitalopram—HRH1—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000212	0.00213	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000212	0.00213	CbGpPWpGaD
Escitalopram—CHRM1—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000211	0.00213	CbGpPWpGaD
Escitalopram—ADRA1A—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000208	0.00209	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000205	0.00207	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.0002	0.00201	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000199	0.002	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000198	0.00199	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000198	0.00199	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000197	0.00198	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000197	0.00198	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000196	0.00197	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000194	0.00195	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000194	0.00195	CbGpPWpGaD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.00019	0.00191	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000189	0.0019	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000189	0.0019	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000189	0.0019	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000186	0.00187	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000186	0.00187	CbGpPWpGaD
Escitalopram—SLC6A4—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000185	0.00186	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000184	0.00185	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000183	0.00184	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00018	0.00181	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000178	0.00179	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000177	0.00178	CbGpPWpGaD
Escitalopram—SLC6A3—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000177	0.00178	CbGpPWpGaD
Escitalopram—CHRM1—Regulation of Actin Cytoskeleton—RAF1—dilated cardiomyopathy	0.000176	0.00177	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000175	0.00176	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000175	0.00176	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000166	0.00167	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000162	0.00163	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000152	0.00153	CbGpPWpGaD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000152	0.00153	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000151	0.00152	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000149	0.0015	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000144	0.00145	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000144	0.00145	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000141	0.00142	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.00014	0.00141	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.00014	0.00141	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000138	0.00139	CbGpPWpGaD
Escitalopram—SLC6A3—Neuronal System—RAF1—dilated cardiomyopathy	0.000135	0.00136	CbGpPWpGaD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000132	0.00132	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000131	0.00132	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000129	0.0013	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000129	0.0013	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000129	0.0013	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ANKRD1—dilated cardiomyopathy	0.000124	0.00124	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000123	0.00124	CbGpPWpGaD
Escitalopram—CHRM1—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	0.000121	0.00121	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.00012	0.00121	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000117	0.00118	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000117	0.00118	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—TAZ—dilated cardiomyopathy	0.000116	0.00117	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000116	0.00117	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	0.000114	0.00114	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000112	0.00112	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000112	0.00112	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000111	0.00112	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000111	0.00112	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.00011	0.0011	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.00011	0.0011	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000109	0.00109	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000107	0.00108	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	0.000107	0.00108	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000107	0.00107	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000105	0.00106	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—SDHA—dilated cardiomyopathy	0.000105	0.00106	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000105	0.00106	CbGpPWpGaD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000104	0.00105	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000104	0.00104	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000103	0.00104	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000102	0.00103	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000101	0.00102	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000101	0.00102	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000101	0.00102	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000101	0.00102	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000101	0.00101	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.0001	0.00101	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	9.95e-05	0.001	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	9.95e-05	0.001	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	9.91e-05	0.000997	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	9.87e-05	0.000993	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	9.67e-05	0.000973	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	9.43e-05	0.000949	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	9.4e-05	0.000946	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	9.4e-05	0.000946	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	9.25e-05	0.000931	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	9.13e-05	0.000919	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	9.1e-05	0.000916	CbGpPWpGaD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	9.02e-05	0.000908	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—AGTR1—dilated cardiomyopathy	9e-05	0.000906	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	9e-05	0.000905	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	8.96e-05	0.000902	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	8.86e-05	0.000891	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	8.59e-05	0.000864	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	8.56e-05	0.000861	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8.54e-05	0.000859	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	8.43e-05	0.000848	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	8.22e-05	0.000828	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	8.15e-05	0.00082	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	8.12e-05	0.000817	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	7.99e-05	0.000804	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	7.8e-05	0.000785	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.79e-05	0.000783	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	7.77e-05	0.000782	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	7.65e-05	0.00077	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	7.43e-05	0.000748	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	7.4e-05	0.000744	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	7.37e-05	0.000742	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—RAC1—dilated cardiomyopathy	7.3e-05	0.000734	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	7.29e-05	0.000733	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	7.26e-05	0.00073	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	6.99e-05	0.000703	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—AGT—dilated cardiomyopathy	6.97e-05	0.000702	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.91e-05	0.000696	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.91e-05	0.000696	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PSEN2—dilated cardiomyopathy	6.75e-05	0.000679	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PSEN2—dilated cardiomyopathy	6.72e-05	0.000677	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.63e-05	0.000667	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	6.62e-05	0.000666	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.43e-05	0.000647	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	6.41e-05	0.000645	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—AGT—dilated cardiomyopathy	6.33e-05	0.000637	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	6.32e-05	0.000636	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	6.32e-05	0.000636	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	6.3e-05	0.000634	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	6.24e-05	0.000628	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.22e-05	0.000626	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	6.21e-05	0.000624	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—AGT—dilated cardiomyopathy	6.04e-05	0.000608	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—AGT—dilated cardiomyopathy	6.02e-05	0.000606	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.99e-05	0.000603	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.99e-05	0.000603	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.97e-05	0.000601	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.97e-05	0.000601	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—AGT—dilated cardiomyopathy	5.93e-05	0.000597	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.88e-05	0.000591	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.88e-05	0.000591	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—RAC1—dilated cardiomyopathy	5.74e-05	0.000578	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—RAC1—dilated cardiomyopathy	5.72e-05	0.000576	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—RAC1—dilated cardiomyopathy	5.64e-05	0.000567	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	5.62e-05	0.000566	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CXCR3—dilated cardiomyopathy	5.57e-05	0.00056	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CXCR3—dilated cardiomyopathy	5.55e-05	0.000559	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—AGT—dilated cardiomyopathy	5.49e-05	0.000552	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—AGT—dilated cardiomyopathy	5.47e-05	0.00055	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	5.46e-05	0.00055	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.39e-05	0.000543	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—AGT—dilated cardiomyopathy	5.38e-05	0.000542	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.38e-05	0.000541	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.32e-05	0.000535	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.29e-05	0.000533	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.04e-05	0.000507	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.61e-05	0.000464	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.59e-05	0.000462	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.52e-05	0.000455	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.39e-05	0.000442	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.37e-05	0.00044	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.36e-05	0.000438	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.33e-05	0.000436	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.29e-05	0.000431	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—RAC1—dilated cardiomyopathy	3.92e-05	0.000394	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.81e-05	0.000383	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.8e-05	0.000382	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.75e-05	0.000378	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.74e-05	0.000377	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—AGT—dilated cardiomyopathy	3.74e-05	0.000376	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.74e-05	0.000376	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.68e-05	0.000371	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—RAC1—dilated cardiomyopathy	3.39e-05	0.000341	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—RAC1—dilated cardiomyopathy	3.38e-05	0.00034	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—RAC1—dilated cardiomyopathy	3.33e-05	0.000335	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—AGT—dilated cardiomyopathy	3.24e-05	0.000326	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—AGT—dilated cardiomyopathy	3.23e-05	0.000325	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—AGT—dilated cardiomyopathy	3.18e-05	0.00032	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.01e-05	0.000303	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GPX1—dilated cardiomyopathy	2.86e-05	0.000287	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CD36—dilated cardiomyopathy	2.78e-05	0.00028	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	2.63e-05	0.000264	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.61e-05	0.000263	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.6e-05	0.000262	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—RAF1—dilated cardiomyopathy	2.6e-05	0.000261	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.56e-05	0.000258	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	2.56e-05	0.000257	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—AGT—dilated cardiomyopathy	2.5e-05	0.000252	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	2.3e-05	0.000232	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—RAF1—dilated cardiomyopathy	2.25e-05	0.000226	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—RAF1—dilated cardiomyopathy	2.24e-05	0.000226	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—RAF1—dilated cardiomyopathy	2.21e-05	0.000222	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—EGFR—dilated cardiomyopathy	1.78e-05	0.000179	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	1.72e-05	0.000173	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	1.67e-05	0.000168	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.54e-05	0.000155	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.54e-05	0.000155	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EGFR—dilated cardiomyopathy	1.51e-05	0.000152	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	1.51e-05	0.000152	CbGpPWpGaD
